Breakthrough Cancer Pain: a Comparison of Surveys with European and Canadian Patients

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2014 Sep 7

PMID 25193599

Citations 15

Authors

Gillian Bedard

Andrew Davies

Rachel McDonald

Philippa Hawley

Alison Buchanan

Marko Popovic

Erin Wong

Edward Chow

Affiliations

Soon will be listed here.

Abstract

Introduction: Breakthrough cancer pain is defined as a transient exacerbation of pain that occurs spontaneously or in response to a trigger, despite stable and controlled background pain. Breakthrough pain often causes significant functional impairments for patients and can decrease quality of life.

Objective: The objective of the study was to determine differences between breakthrough cancer pain incidence and management in Canada and Europe.

Methods: Data collected from previous studies of breakthrough cancer pain in Canada and Europe was compared. A standard survey with identical inclusion/exclusion criteria was utilized for both patient populations.

Results: Both groups of patients had a similar number and duration of breakthrough pain episodes, and similar pain intensity and pain interference with their daily activities. European patients reported better analgesic efficacy and satisfaction with management, and a greater percentage of European patients were prescribed a transmucosal fentanyl formulation (19.1 vs 2.9 %). More European patients (55 %) than Canadian patients (32.5 %) took their rescue medication every time they had a breakthrough pain episode.

Conclusions: Breakthrough cancer pain in both Canadian and European patients greatly impacts their daily living, and both groups of patients had similar experiences with breakthrough cancer pain. Currently, this pain is not adequately managed for many patients. The role for new analgesic treatments in management of breakthrough cancer pain needs further study.

Citing Articles

Scheduled and Breakthrough Opioid Use for Cancer Pain in an Inpatient Setting at a Tertiary Cancer Hospital.

De Moraes A, Erdogan E, Azhar A, Reddy S, Lu Z, Geller J Curr Oncol. 2024; 31(3):1335-1347.

PMID: 38534934 PMC: 10969060. DOI: 10.3390/curroncol31030101.

Breakthrough and Episodic Cancer Pain from a Palliative Care Perspective.

Lohre E, Jakobsen G, Solheim T, Klepstad P, Thronaes M Curr Oncol. 2023; 30(12):10249-10259.

PMID: 38132380 PMC: 10742182. DOI: 10.3390/curroncol30120746.

Multidisciplinary approach, continuous care and opioid management in cancer pain: case series and review of the literature.

Porzio G, Capela A, Giusti R, Lo Bianco F, Moro M, Ravoni G Drugs Context. 2023; 12.

PMID: 37077766 PMC: 10108666. DOI: 10.7573/dic.2022-11-7.

High-rate breakthrough cancer pain and tumour characteristics - literature review and case series.

Cuomo A, Boutis A, Colonese F, Nocerino D Drugs Context. 2023; 12.

PMID: 36926050 PMC: 10012833. DOI: 10.7573/dic.2022-11-1.

Relationship between breakthrough cancer pain, background cancer pain and analgesic treatment - case series and review of the literature.

Batistaki C, Graczyk M, Janecki M, Lewandowska A, Moutinho R, Vagdatli K Drugs Context. 2023; 11.

PMID: 36660261 PMC: 9828877. DOI: 10.7573/dic.2022-9-4.

References

Davis M . Fentanyl for breakthrough pain: a systematic review. Expert Rev Neurother. 2011; 11(8):1197-216. DOI: 10.1586/ern.11.63. View

Mercadante S, Arcuri E . Pharmacological management of cancer pain in the elderly. Drugs Aging. 2007; 24(9):761-76. DOI: 10.2165/00002512-200724090-00004. View

Deandrea S, Corli O, Consonni D, Villani W, Greco M, Apolone G . Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature. J Pain Symptom Manage. 2013; 47(1):57-76. DOI: 10.1016/j.jpainsymman.2013.02.015. View

Bedard G, Hawley P, Zhang L, Slaven M, Gagnon P, Bisland S . A survey of Canadian cancer patients' perspectives on the characteristics and treatment of breakthrough pain. Support Care Cancer. 2013; 21(9):2557-63. DOI: 10.1007/s00520-013-1817-4. View

Ward S, Goldberg N, Mueller C, Nolan A, Robbins A, Stormoen D . Patient-related barriers to management of cancer pain. Pain. 1993; 52(3):319-324. DOI: 10.1016/0304-3959(93)90165-L. View

Black B, Herr K, Fine P, Sanders S, Tang X, Bergen-Jackson K . The relationships among pain, nonpain symptoms, and quality of life measures in older adults with cancer receiving hospice care. Pain Med. 2011; 12(6):880-9. PMC: 3117028. DOI: 10.1111/j.1526-4637.2011.01113.x. View

Ferrell B, Juarez G . Cancer pain education for patients and the public. J Pain Symptom Manage. 2002; 23(4):329-36. DOI: 10.1016/s0885-3924(02)00380-9. View

Davies A, Buchanan A, Zeppetella G, Porta-Sales J, Likar R, Weismayr W . Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manage. 2013; 46(5):619-28. DOI: 10.1016/j.jpainsymman.2012.12.009. View

van den Beuken-van Everdingen M, de Rijke J, Kessels A, Schouten H, van Kleef M, Patijn J . Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007; 18(9):1437-49. DOI: 10.1093/annonc/mdm056. View

10.

Mercadante S, Radbruch L, Caraceni A, Cherny N, Kaasa S, Nauck F . Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer. 2002; 94(3):832-9. DOI: 10.1002/cncr.10249. View

11.

Mercadante S, Ferrera P, Adile C, Casuccio A . Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose. J Pain Symptom Manage. 2011; 42(3):464-9. DOI: 10.1016/j.jpainsymman.2010.12.010. View

12.

Davies A, Dickman A, Reid C, Stevens A, Zeppetella G . The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2008; 13(4):331-8. DOI: 10.1016/j.ejpain.2008.06.014. View

13.

Webber K, Davies A, Cowie M . Breakthrough pain: a qualitative study involving patients with advanced cancer. Support Care Cancer. 2010; 19(12):2041-6. DOI: 10.1007/s00520-010-1062-z. View

14.

Davies A, Zeppetella G, Andersen S, Damkier A, Vejlgaard T, Nauck F . Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain. 2011; 15(7):756-63. DOI: 10.1016/j.ejpain.2010.12.004. View

15.

Mercadante S . Pharmacotherapy for breakthrough cancer pain. Drugs. 2012; 72(2):181-90. DOI: 10.2165/11597260-000000000-00000. View